Skip to Main Content
Try STAT+ TODAY
Trending:
Health
Biotech
STAT+
First Opinion
The Readout

An IDO takeback & an AACR showdown

  • Damian Garde
  • Meghana Keshavan

By Damian Garde and Meghana Keshavan April 16, 2018

Reprints
The READOUT
Alex Hogan/STAT

The Readout for April 16, 2018

About the Authors Reprints

Damian Garde

Damian Garde

National Biotech Reporter

Damian Garde covers biotech, is a co-writer of The Readout newsletter, and a co-host of "The Readout LOUD" podcast.

Meghana Keshavan

Meghana Keshavan

Biotech Correspondent

Meghana Keshavan covers biotech and contributes to The Readout newsletter.

How Tennessee is creating new opportunities for doctors trained…
How Tennessee is creating new opportunities for doctors trained outside the U.S.
Revenge of the gaslit patients: Now, as scientists, they’re…
Revenge of the gaslit patients: Now, as scientists, they’re tackling Ehlers-Danlos syndromes
Dope Sick: A harrowing story of best friends, addiction…
Dope Sick: A harrowing story of best friends, addiction — and a stealth killer
Regeneron targets obesity, a new microbiome deal, & comparing…
Regeneron targets obesity, a new microbiome deal, & comparing cancer drug costs
Should the feds investigate Aduhelm? Plus: biotech’s biggest binaries…
Should the feds investigate Aduhelm? Plus: biotech’s biggest binaries & regenerating heart tissue
Docs disagree with FDA on Aduhelm, Swiss giants pinch…
Docs disagree with FDA on Aduhelm, Swiss giants pinch pennies, & one SPAC makes it rain

Recommended Stories